Literature DB >> 20832586

Combined application of blocking antibodies and MicroRNA interference in inhibiting CD44 expression.

W Shao1, J-B Chen, F Wang, J-J Xia, Z-Q Qi.   

Abstract

BACKGROUND: We sought to explore the effect of CD44 targeting on the tolerance to memory cell-mediated graft rejection.
METHODS: We developed a cardiac transplantation model in nude mice and administered anti-CD44 monoclonal antibodies (mAbs) to these mice. Then, we used anti-CD44 mAb and CD44-interfering microRNA (miRNA) to inhibit CD44 expression in vitro.
RESULTS: The median survival time (MST) associated with multiple intraperitoneal injections was >100 days, whereas that associated with CD4(+) Tm cells blocked CD44 and that associated with a single intraperitoneal injection of anti-CD44 mAb was 11 and 10.3 days, control group was 5.5 days. The inhibition effect of the anti-CD44 mAb in 3T3 cells significantly reduced with cell proliferation. Used CD44 miRNA in 3T3 cells, the most obvious inhibition effect of mRNA appeared at 48 hours after transfection and the inhibition decreased subsequently. In combination, antibody-mediated blocking and miRNA showed some synergistic effects.
CONCLUSION: The inhibition of CD44 can significantly prolong the MST in memory models. The inhibition effect of combined application showed limitations with regard to cell proliferation and duration of action, but the short-term synergistic effect of the combined approach was stronger than the effects of individual approaches. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832586     DOI: 10.1016/j.transproceed.2010.05.149

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines.

Authors:  Jon C Henry; Jong-Kook Park; Jinmai Jiang; Ji Hye Kim; David M Nagorney; Lewis R Roberts; Soma Banerjee; Thomas D Schmittgen
Journal:  Biochem Biophys Res Commun       Date:  2010-11-03       Impact factor: 3.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.